Login / Signup

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Hui Ming LinBrian Y LeeLesley CastilloCalan SpielmanJudith GroganNicole K YeungJames G KenchPhillip D StrickerAnne-Maree HaynesMargaret M CenteneraLisa M ButlerS Martin ShreeveLisa G HorvathRoger J Daly
Published in: The Prostate (2018)
Our findings suggest that co-administration of the FAK inhibitor, VS-6063, with docetaxel represents a potential therapeutic strategy to overcome docetaxel resistance in prostate cancer.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • locally advanced
  • cell migration
  • squamous cell carcinoma
  • radiation therapy